Erlocip 100 Tablet contains erlotinib (100mg), a tyrosine kinase inhibitor specifically designed to target epidermal growth factor receptor (EGFR) in cancer cells. This lower-dose formulation is primarily used for pancreatic cancer treatment and as maintenance therapy for non-small cell lung cancer (NSCLC). The 100mg strength allows for precise dosing adjustments based on patient tolerance and drug interactions. As a targeted therapy, Erlocip offers a more focused approach than conventional chemotherapy, particularly effective in EGFR mutation-positive cancers. Patients typically take one tablet daily on an empty stomach, with treatment response monitored through regular imaging and symptom evaluation.

Uses of Erlocip 100 Tablet:

• Maintenance therapy for advanced NSCLC
• Treatment of metastatic pancreatic cancer (with gemcitabine)
• Therapy for NSCLC patients with dose reduction needs
• Management of EGFR mutation-positive NSCLC in specific cases

Benefits of Erlocip 100 Tablet:

• Lower dose option for improved tolerability
• Targeted action against EGFR pathways
• Oral administration for convenient treatment
• Proven survival benefit in pancreatic cancer
• Maintains quality of life during therapy

Side Effects of Erlocip 100 Tablet:

Very common (>10%):
• Skin rash (60%, usually grade 1-2)
• Diarrhea (45%)
• Fatigue (35%)
• Anorexia (30%)

Serious (1-10%):
• Interstitial lung disease (1%)
• Severe hepatotoxicity
• Gastrointestinal perforation
• Ocular disorders

How to Use Erlocip 100 Tablet?

• Standard dose: 100mg once daily
• Administration: On empty stomach (1h before/2h after meals)
• Hydration: Maintain fluids to manage diarrhea
• Skin care: Begin moisturizing regimen at treatment start
• Monitoring: Regular LFTs and clinical assessments

How Erlocip 100 Tablet Works?

Erlocip 100 competitively inhibits EGFR tyrosine kinase, blocking the phosphorylation and activation of downstream signaling proteins. This interruption of the RAS-RAF-MEK-ERK pathway prevents cancer cell proliferation and induces apoptosis. The 100mg dose provides sufficient receptor coverage while minimizing adverse effects, particularly important for long-term maintenance therapy.

Safety Advice:

• Pregnancy: Category D – Absolute contraindication
• Smoking: Requires dose adjustment (increases clearance)
• PPIs: Contraindicated (space H2 blockers by 10h)
• Photoprotection: Essential due to photosensitivity
• Liver monitoring: Baseline and periodic LFTs required
• Drug interactions: Many via CYP3A4 pathway

What If You Miss a Dose?

If <12 hours late: Take immediately with water
If >12 hours late: Skip dose entirely
Never take two doses within 24 hours

FAQs:

Q1. Why would my doctor prescribe 100mg instead of 150mg?

The 100mg dose is often used for pancreatic cancer treatment, for patients requiring dose reduction due to side effects, or those taking interacting medications that increase erlotinib levels.

Q2. How should I manage diarrhea from Erlocip?

Start loperamide at first loose stool (4mg initially, then 2mg after each episode). Maintain hydration and report diarrhea lasting >48 hours.

Q3. Can I take antacids with this medication?

Antacids may be taken at least 2 hours before or after Erlocip. PPIs should be avoided entirely as they significantly reduce absorption.

Q4. What’s the significance of the skin rash?

Rash often correlates with treatment response in NSCLC. Manage with topical steroids and antibiotics – never stop treatment without consulting your oncologist.

Q5. How will we know if the treatment is working?

Response is assessed through CT scans every 8-12 weeks, symptom improvement, and for NSCLC patients, monitoring of circulating tumor DNA when available.

Q6. Can I drink grapefruit juice while on Erlocip?

No – grapefruit inhibits CYP3A4 and may dangerously increase erlotinib levels. Avoid all grapefruit products during treatment.

Q7. What eye symptoms require immediate attention?

Severe eye pain, vision changes, or light sensitivity may indicate serious ocular toxicity and require urgent ophthalmologic evaluation.